Report Contents
Market Overview
The global Continuous Glucose Monitoring (CGM) market is emerging as a high-growth segment in diabetes care, generating an estimated revenue base in the mid-2020s that is projected to reach USD 18.00 billion in 2026 and USD 30.60 billion by 2032, reflecting a compound annual growth rate of 9.10% from 2026 to 2032. This expansion is driven by rising diabetes prevalence, rapid adoption of sensor-based glucose tracking, and payer recognition of CGM’s ability to reduce costly acute complications through real-time glycemic insights.
To compete effectively, industry participants must prioritize scalability of device manufacturing, robust localization of software and clinical workflows for regional reimbursement regimes, and seamless technological integration with insulin pumps, digital therapeutics, and electronic health records. Converging trends in miniaturized biosensors, cloud analytics, and personalized decision-support algorithms are broadening CGM’s scope from a specialist tool to a mainstream standard of care, reshaping competitive dynamics and regulatory expectations. This report is positioned as a critical strategic tool, providing forward-looking insight into capital allocation, portfolio choices, partnership structures, and regulatory inflection points that will define the next phase of transformation in the CGM industry.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Continuous Glucose Monitoring Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Continuous Glucose Monitoring Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Sensor-based continuous glucose monitoring systems:
Sensor-based continuous glucose monitoring systems currently represent the core of the market, as they provide real-time interstitial glucose data with update intervals as short as five minutes. Their dominant position is reinforced by widespread adoption among insulin-dependent patients who require high-frequency glucose profiling to avoid hypoglycemia and hyperglycemia. In terms of quantitative performance, modern sensors achieve mean absolute relative differences that often fall in the low double-digit percentage range, which is sufficient for therapeutic decision-making without frequent confirmatory fingerstick tests.
The competitive advantage of sensor-based systems lies in their ability to deliver continuous trend data and predictive alerts, which can reduce severe hypoglycemic events for a significant portion of high-risk users compared with traditional self-monitoring of blood glucose. Many platforms offer wear durations ranging from seven to fourteen days per sensor, which lowers insertion frequency and improves adherence while also reducing per-day consumable costs. The primary growth catalyst for this type is the expanding reimbursement coverage for continuous glucose monitoring in both public and private insurance schemes, which is accelerating replacement of legacy glucose meters in North America, Europe and an increasing number of Asia-Pacific markets.
-
Integrated insulin pump and continuous glucose monitoring systems:
Integrated insulin pump and continuous glucose monitoring systems occupy a rapidly expanding premium segment, where closed-loop or hybrid closed-loop solutions automate insulin delivery based on continuous glucose data. These systems are especially significant for intensive insulin therapy users who require tight glycemic control and benefit from reduced manual dosing decisions. Many integrated platforms demonstrate meaningful reductions in time spent in hypo- and hyperglycemic ranges, while increasing time-in-range to well above fifty percent for a substantial share of adherent patients.
The key competitive advantage of integrated systems is their algorithm-driven feedback loop, which can automatically modulate basal insulin rates and deliver correction boluses, thereby lowering user burden and improving adherence relative to standalone pumps and sensors. Several commercial systems report reductions in glycated hemoglobin levels by measurable fractions of a percentage point, translating into lower long-term complication risk and health care utilization. The primary catalyst fueling growth in this segment is the rapid advancement of dosing algorithms and interoperability standards, which support integration between pumps, sensors and mobile applications, enabling more personalized and adaptive insulin delivery strategies.
-
Standalone continuous glucose monitoring transmitters and receivers:
Standalone continuous glucose monitoring transmitters and receivers form a critical hardware layer that bridges sensors with end-user interfaces such as handheld receivers and smartphones. Although some newer solutions leverage direct-to-smartphone connectivity, dedicated transmitters and receivers remain significant in regions or patient groups where mobile device compatibility, connectivity reliability or regulatory constraints limit exclusive smartphone use. These components typically support multi-day or multi-week operation per charge, which ensures consistent data capture throughout the sensor wear period.
The competitive strength of standalone transmitters and receivers lies in their robust wireless communication, often using low-energy protocols to maintain reliable connections with minimal battery consumption. Many systems sustain stable data transmission over several meters, reducing dropouts during everyday activities and thereby improving the continuity of glucose trend data and alarm reliability. Their growth is driven primarily by ongoing enhancements in low-power electronics and wireless chipsets, as well as regulatory acceptance of remote monitoring features that allow data sharing with caregivers and clinicians in both home and institutional settings.
-
Continuous glucose monitoring data management and analytics software:
Continuous glucose monitoring data management and analytics software has evolved into a strategic value layer, transforming raw glucose readings into actionable clinical and behavioral insights. This category is increasingly central to differentiation as hardware performance converges, because providers and payers seek platforms that can aggregate multi-day glucose profiles, insulin dosing records and lifestyle data into integrated reports. Many software solutions can process thousands of glucose data points per patient per day, which far exceeds the data density achievable with fingerstick monitoring.
The competitive advantage of analytics software stems from its ability to generate visual trend reports, automated pattern recognition and risk scoring that support therapy optimization and telemedicine workflows. Platforms that quantify time-in-range, glycemic variability and nocturnal hypoglycemia burden give clinicians concrete metrics to guide treatment adjustments and demonstrate outcomes to payers. Growth in this segment is propelled by the broader digital health transformation, including cloud-based data platforms, application programming interfaces that link with electronic health records and remote patient monitoring programs that reimburse clinicians for reviewing continuous glucose data.
-
Professional and clinic-based continuous glucose monitoring systems:
Professional and clinic-based continuous glucose monitoring systems are primarily deployed in endocrinology practices, diabetes clinics and hospital settings for short-term diagnostic evaluations. These systems are significant because they provide structured, retrospective glucose profiles over periods such as seven to fourteen days, allowing clinicians to assess therapy effectiveness and identify postprandial spikes or nocturnal hypoglycemia in patients who do not yet use personal continuous monitoring. In many markets, a sizable subset of type 2 diabetes patients undergoes professional monitoring as part of periodic treatment optimization.
The competitive edge of professional systems lies in their disposable or semi-disposable sensors combined with clinic-owned readers and analytics tools, which reduce upfront costs for patients while enabling high-throughput deployment across large patient panels. Clinics can monitor a considerable number of patients per device over a year, which improves asset utilization and supports population-level glycemic management initiatives. The primary growth catalyst for this type is the increasing incorporation of professional continuous monitoring into standardized diabetes care pathways and quality improvement programs, particularly as payers recognize its value in preventing costly complications through more timely therapy intensification.
-
Continuous glucose monitoring accessories and consumables:
Continuous glucose monitoring accessories and consumables encompass insertion devices, adhesives, tapes, chargers and related components that support sensor wear, device protection and user comfort. This segment is strategically important because it generates recurring revenue and directly influences user adherence, as issues such as skin irritation or premature sensor detachment can undermine clinical benefits. For many platforms, consumables account for a significant portion of the total lifetime cost of ownership, making this category financially material for manufacturers.
The competitive advantage of high-quality accessories and consumables is reflected in improved sensor wear-time reliability and reduced failure rates, which in turn help users maintain near-continuous data availability over each wear cycle. Adhesive solutions that reliably secure sensors through exercise, perspiration and everyday movement can lower early replacement incidents and thus reduce per-day costs while preserving data integrity. Growth in this segment is driven by expanding installed bases of continuous monitoring users, as well as incremental innovation in hypoallergenic materials and low-profile insertion tools that reduce discomfort and make self-application more feasible for newly diagnosed patients and older adults.
Market By Region
The global Continuous Glucose Monitoring market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents the strategic anchor of the Continuous Glucose Monitoring market, with the United States and Canada driving high adoption of sensor-based glucose tracking, cloud-connected insulin management, and AI-enabled decision support tools. The region accounts for a significant portion of the global market, acting as a mature, high-value revenue base that underpins global stability and validates premium pricing for advanced CGM platforms and integrated insulin pump systems.
Untapped potential in North America lies in Medicaid and underinsured populations, rural diabetes clinics, and long-term care facilities where CGM penetration remains limited. Key challenges include reimbursement disparities between states, clinician workload constraints that slow CGM onboarding, and digital literacy gaps in elderly Type 2 diabetes patients. Addressing these barriers through simplified onboarding, remote patient monitoring workflows, and outcomes-based contracting can unlock incremental sensor volume and subscription-based data services.
-
Europe:
Europe is a strategically important Continuous Glucose Monitoring region, characterized by strong clinical guidelines, robust public reimbursement frameworks, and a growing emphasis on value-based diabetes care. Markets such as Germany, the United Kingdom, France, Italy, and the Nordics act as primary revenue drivers, making Europe a substantial contributor to global CGM revenue and an important reference region for health technology assessment outcomes and long-term cost-effectiveness data.
The region contributes a sizeable share of the global market, with relatively stable, recurring revenue from established Type 1 diabetes cohorts and expanding coverage for high-risk Type 2 patients. However, substantial growth potential remains in Eastern and Southern Europe, where CGM reimbursement is more fragmented and adoption in public hospitals and primary care networks is still emerging. Overcoming budget impact concerns, navigating heterogeneous payer requirements, and localizing patient education materials will be critical to convert pilot programs into large-scale CGM deployments.
-
Asia-Pacific:
The broader Asia-Pacific Continuous Glucose Monitoring market holds exceptional strategic importance because of its large diabetic population, rising healthcare expenditures, and rapid digital health adoption. Countries such as India, Australia, Singapore, and emerging Southeast Asian economies are primary drivers of regional activity, collectively positioning Asia-Pacific as a high-growth engine for sensor shipments and mobile app–based glucose analytics within the global market valued at around 16.50 Billion in 2025.
Asia-Pacific currently accounts for a growing yet still underpenetrated share of global CGM revenue and is expected to contribute disproportionately to the projected expansion toward 30.60 Billion by 2032 at a 9.10% CAGR. Significant untapped potential exists in Tier 2 and Tier 3 cities, public diabetes programs, and employer-sponsored health plans. Key challenges include affordability constraints, limited endocrinology capacity, and variability in regulatory timelines. Scalable subscription pricing, partnerships with telemedicine platforms, and locally manufactured sensors can help unlock this latent demand.
-
Japan:
Japan is a strategically distinct Continuous Glucose Monitoring market within Asia, characterized by an aging population, high Type 2 diabetes prevalence, and advanced digital infrastructure. As one of the most sophisticated healthcare systems in the region, Japan contributes a meaningful share of Asia-Pacific CGM revenue and serves as a reference market for closed-loop insulin delivery and hospital-based glycemic control solutions.
The country’s contribution to global expansion is moderate but highly stable, anchored by strong physician acceptance and structured reimbursement for eligible patients. Despite this, there remains untapped opportunity in primary care clinics, corporate wellness programs, and remote monitoring of elderly patients living alone. Key barriers include conservative prescribing patterns, administrative burden for reimbursement documentation, and the need for highly localized user interfaces. Streamlined reimbursement workflows and integration with domestic electronic medical record systems will be essential to capture additional growth.
-
Korea:
Korea occupies a strategically important niche in the Continuous Glucose Monitoring landscape, combining rapid digital health adoption with high smartphone penetration and strong government interest in chronic disease management. The market is primarily driven by South Korea, which demonstrates increasing uptake of wearable sensors, mobile-enabled diabetes coaching, and hospital-linked CGM platforms, making it an important innovation testbed within Asia-Pacific.
Although Korea represents a smaller share of global CGM revenue compared with major Western markets, its growth rate is robust and contributes meaningfully to regional expansion. Untapped potential lies in broader reimbursement coverage for Type 2 diabetes, integration of CGM data into national health check-up programs, and expansion into secondary cities beyond Seoul and Busan. Key challenges include pricing pressure from national health insurance, competitive expectations for rapid product iteration, and the need for strong data security compliance. Strategic partnerships with local hospital systems and digital therapeutics companies can accelerate penetration.
-
China:
China is one of the most strategically critical regions for the future of the Continuous Glucose Monitoring market, given its large and growing diabetic population and rapidly scaling middle class. Major urban centers such as Beijing, Shanghai, Guangzhou, and Shenzhen currently lead adoption, supported by tertiary hospitals and self-pay patients who drive demand for real-time glucose sensors and app-integrated diabetes management platforms.
China’s share of the global market is expanding quickly and is expected to become a major driver of overall growth as the industry moves from 18.00 Billion in 2026 toward long-term projections. There is substantial untapped potential in public hospital systems, community health centers, and lower-tier cities where awareness and reimbursement remain limited. Key barriers include price sensitivity, provincial reimbursement variability, and strong local competition from domestic sensor manufacturers. Localized manufacturing, tiered product portfolios, and partnerships with national digital platforms and pharmacy chains will be critical to unlock large-scale CGM adoption.
-
USA:
The USA is the single most influential country-level market for Continuous Glucose Monitoring, accounting for a dominant share of North American revenue and setting global benchmarks in clinical guidelines, reimbursement models, and integrated diabetes technology ecosystems. High adoption among Type 1 patients, increasing use in insulin-treated Type 2 populations, and strong penetration of hybrid closed-loop systems position the USA as a core engine of global market growth.
The country contributes a substantial portion of the global total and provides a mature, innovation-driven revenue base that supports ongoing research and development investment. Despite this, meaningful untapped potential persists among primary care–managed Type 2 patients, rural and low-income populations, and employer-sponsored health plans seeking to reduce diabetes-related medical costs. Major challenges include reimbursement complexity between commercial and government payers, prior authorization burden, and disparities in digital access. Streamlined coverage policies, value-based contracting, and expanded use of remote patient monitoring codes can further scale CGM adoption across the US healthcare system.
Market By Company
The Continuous Glucose Monitoring market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Dexcom Inc.:
Dexcom Inc. occupies a leading position in the global Continuous Glucose Monitoring market, with its G6 and G7 real-time CGM systems widely adopted in both intensive insulin therapy and broader type 2 diabetes segments. The company is a primary reference point for sensor accuracy, low-latency data transmission and seamless integration with insulin pumps and digital diabetes management platforms. Its installed base and recurring sensor revenue create a resilient business model that anchors its relevance across North America, Europe and increasingly in Asia-Pacific markets.
In 2025, Dexcom’s CGM-related revenue in the global market is estimated at USD 4.60 billion with a market share of approximately 27.90%. These figures reflect a strong capture of the projected USD 16.50 billion CGM market size in 2025 and validate Dexcom’s role as one of the primary growth engines in a sector expanding at a 9.10% compound annual growth rate through 2032. The company’s scale allows substantial investment in R&D, clinical studies and patient support programs, reinforcing its competitive edge.
Dexcom’s core competitive advantages include highly accurate sensors, user-friendly mobile applications and proven interoperability with automated insulin delivery systems from players such as Tandem Diabetes Care and Insulet. Its focus on cloud-based analytics, remote monitoring and population health solutions positions it as a strategic partner for payers and integrated delivery networks that are shifting to value-based diabetes care. Compared with emerging low-cost entrants, Dexcom defends a premium positioning based on clinical performance and digital ecosystem strength rather than price alone.
-
Abbott Laboratories:
Abbott Laboratories is a dominant participant in the Continuous Glucose Monitoring market, primarily through its FreeStyle Libre portfolio, which has expanded from flash glucose monitoring toward full CGM functionality. The company plays a pivotal role in driving mass-market adoption, especially among type 2 diabetes patients and payers seeking cost-effective yet clinically impactful glucose monitoring solutions. Its broad international footprint and strong presence in Europe, Latin America and parts of Asia enable rapid scaling compared with many competitors.
For 2025, Abbott’s CGM revenue is estimated at USD 4.30 billion with a market share of about 26.10%. This performance places Abbott in a near-duopolistic position with Dexcom at the top of the market, collectively capturing a significant portion of global CGM expenditure. Abbott’s scale advantages in manufacturing and distribution support aggressive pricing strategies, which in turn accelerate penetration into public health systems and emerging markets where reimbursement budgets are constrained.
Abbott’s strategic differentiation lies in simplified sensor application, longer wear duration and broad reimbursement coverage, which reduce barriers to initiation for both endocrinologists and primary care physicians. Its integration into digital health ecosystems, including proprietary mobile applications and data-sharing platforms, strengthens patient engagement and physician oversight. Relative to innovation-focused challengers, Abbott leverages its diagnostics heritage, extensive regulatory experience and strong payer relationships to maintain high formulary and tender success rates across multiple regions.
-
Medtronic plc:
Medtronic plc is a key integrated player in the Continuous Glucose Monitoring market, particularly at the intersection of CGM and insulin pump therapy for intensive insulin-dependent patients. Its Guardian sensor systems and MiniMed insulin pump platforms are central components of hybrid closed-loop and automated insulin delivery solutions, making Medtronic especially relevant for type 1 diabetes and complex type 2 cases. The company’s portfolio strategy focuses on end-to-end diabetes technology rather than stand-alone sensors alone.
In 2025, Medtronic’s CGM-related revenue is projected to be around USD 2.00 billion, corresponding to a market share of roughly 12.10%. These figures underscore Medtronic’s solid, though not dominant, position compared with pure-play CGM specialists, while its broader diabetes technology franchise provides additional cross-selling and bundling opportunities. The company’s scale in medical devices and established relationships with hospitals and endocrinology clinics support continued growth as the global CGM market approaches USD 18.00 billion in 2026.
Medtronic’s strategic advantages include deep expertise in insulin delivery algorithms, proven experience with closed-loop systems and a global installed base of insulin pumps that create a natural channel for CGM upgrades. Its differentiation is strongest where payers and providers prioritize integrated therapy systems that can reduce severe hypoglycemia, hospitalizations and long-term complications. Compared with lower-cost CGM entrants, Medtronic competes on comprehensive care pathways, device interoperability and clinical outcomes evidence rather than sensor price alone.
-
The Ypsomed Group:
The Ypsomed Group participates in the Continuous Glucose Monitoring landscape primarily through its insulin delivery platforms and partnerships that link its mylife insulin pump systems with third-party CGM technologies. While not a pure-play CGM sensor manufacturer, Ypsomed is strategically important in the broader connected diabetes ecosystem, especially in Europe where its patch pump and pen technologies are well established. Its role focuses on enabling interoperability and patient-centric device design to support CGM-driven insulin titration.
For 2025, Ypsomed’s revenue attributable to CGM-related integrated solutions and connectivity is estimated at USD 0.25 billion with a market share near 1.50%. These figures highlight a niche but growing presence, as the company leverages CGM integration to enhance the value proposition of its pumps and connected pens in a market projected to rise to USD 30.60 billion by 2032. Its influence is more pronounced in the hybrid closed-loop and interoperable device segments rather than in stand-alone sensor volumes.
Ypsomed’s competitive strengths include user-friendly design, modular device architectures and openness to collaboration with multiple CGM and algorithm partners. This interoperability strategy differentiates it from vertically integrated players that lock patients into proprietary ecosystems. By focusing on patient convenience, slim form factors and app-driven therapy support, Ypsomed positions itself as an agile collaborator in the CGM-enabled insulin therapy chain, particularly attractive for health systems seeking flexible, multi-vendor solutions.
-
Senseonics Holdings Inc.:
Senseonics Holdings Inc. is a specialized innovator within the Continuous Glucose Monitoring market, best known for its implantable long-term CGM system, which offers sensor wear durations far exceeding conventional transcutaneous devices. This unique positioning targets patients who value reduced insertion frequency and discreet device profiles, as well as providers focused on improving long-term adherence. Senseonics’ technology broadens the clinical options in CGM beyond the traditional wearable sensor paradigm.
In 2025, Senseonics’ CGM revenue is expected to be around USD 0.18 billion, with an estimated market share of 1.10%. While modest relative to industry leaders, these figures demonstrate traction for a differentiated, procedure-based CGM model within a market that is rapidly expanding at a 9.10% CAGR. The need for physician involvement in implantation and removal shapes its geographic expansion strategy and influences payer negotiations and reimbursement coding.
Senseonics’ strategic differentiation is anchored in long-term implantable sensor technology, reduced daily patient burden and stable signal quality over extended wear periods. Partnerships with distribution and clinical service organizations enhance its reach, particularly in the United States and selected European markets. Compared with mainstream CGM vendors, Senseonics competes less on disposable sensor volume and more on patient adherence, convenience over months rather than days and integration into endocrinology clinic workflows.
-
Ascensia Diabetes Care:
Ascensia Diabetes Care, historically recognized for blood glucose monitoring systems, has transitioned into the Continuous Glucose Monitoring space through partnership-driven approaches and portfolio expansion. Its role in the CGM market centers on leveraging its strong relationships with endocrinologists, primary care physicians and payers to introduce next-generation CGM options to a broad diabetic population. The company’s commercial infrastructure and brand recognition in self-monitoring of blood glucose provide a foundation for CGM cross-selling.
By 2025, Ascensia’s CGM-related revenue is estimated at USD 0.26 billion with a market share of approximately 1.60%. These metrics indicate an emerging presence, as the company pivots from legacy glucose strip revenues toward subscription and sensor-based revenue streams aligned with the evolving CGM market structure. Its financial trajectory will depend on the pace of adoption among long-standing fingerstick users and on securing reimbursement across key markets.
Ascensia’s competitive strengths include extensive global distribution channels, a sizable installed user base from traditional glucose meters and well-established payer relationships. By bundling CGM offerings with digital coaching, data analytics and educational programs, the company differentiates itself as a comprehensive diabetes management partner rather than a pure device supplier. This strategy positions Ascensia to capture patients transitioning from intermittent blood glucose monitoring to continuous data-driven therapy optimization.
-
Insulet Corporation:
Insulet Corporation plays a critical role in the Continuous Glucose Monitoring environment through its Omnipod tubeless insulin pump platform, which integrates closely with leading CGM systems in automated insulin delivery configurations. Although Insulet does not manufacture CGM sensors, its business is deeply intertwined with CGM usage, because closed-loop performance depends on high-quality continuous glucose data. The company is thus a strategic stakeholder in CGM adoption, especially in established type 1 markets and among tech-savvy patients seeking tubing-free solutions.
Insulet’s revenue linked to CGM-enabled insulin delivery, including systems that rely on CGM data for automation, is projected to be around USD 1.00 billion in 2025, corresponding to an approximate market share of 6.10% when viewed within the broader CGM-driven therapy value chain. These figures highlight Insulet’s importance as a demand amplifier for CGM sensors, even if the company does not directly record sensor sales. As automated insulin delivery gains share, Insulet’s volumes tend to scale in tandem with CGM penetration.
Insulet’s strategic advantages derive from its tubeless patch pump design, strong user satisfaction metrics and robust integrations with leading CGM providers. By focusing on ease of use, discreet wearability and flexible lifestyle fit, Insulet attracts patients who are often early adopters of advanced CGM systems. Compared with traditional pump manufacturers, Insulet differentiates through simplicity and patient empowerment, which in turn drives sustained CGM utilization and strengthens its partnerships within the CGM ecosystem.
-
Tandem Diabetes Care Inc.:
Tandem Diabetes Care Inc. is a pivotal participant in the Continuous Glucose Monitoring ecosystem, primarily through its t:slim X2 and related insulin pump platforms that integrate deeply with leading CGM technologies for hybrid closed-loop functionality. Its portfolio targets insulin-intensive patients who prioritize algorithm-driven glucose control, customizable user interfaces and reliable connectivity. Tandem’s business model is closely tied to CGM expansion because the clinical value of its automated features depends on continuous sensor data.
In 2025, Tandem’s CGM-integrated pump and software revenue is estimated at USD 0.95 billion, representing an approximate market share of 5.80% within the CGM-enabled diabetes technology space. These figures underline Tandem’s status as a significant, though not dominant, player whose success is correlated with rising global CGM utilization. As health systems increasingly recognize the cost savings from reducing severe hypoglycemia and improving time-in-range, Tandem’s integrated offerings become more attractive.
Tandem’s competitive differentiation stems from its patient-centric pump design, software upgrade capability via remote downloads and sophisticated insulin dosing algorithms tuned to CGM inputs. Collaboration with leading CGM manufacturers enables Tandem to offer patients choice and maintain compatibility with the most advanced sensors. Compared with larger diversified device companies, Tandem’s focused specialization in insulin pump–CGM integration allows for faster innovation cycles and more responsive feature enhancements.
-
Roche Diabetes Care:
Roche Diabetes Care, a long-standing leader in blood glucose monitoring, has been evolving its role in the Continuous Glucose Monitoring market through digital platforms and partnerships that integrate CGM data into comprehensive diabetes management solutions. While Roche’s footprint in stand-alone CGM sensors is more limited than that of category leaders, its software, data analytics and connectivity tools make it an influential orchestrator of multi-source glucose data. This positions Roche as an important enabler of CGM adoption within broader chronic disease management frameworks.
For 2025, Roche’s CGM-associated revenue, including platforms and integrated solutions, is estimated at USD 0.33 billion, corresponding to a market share of around 2.00%. These numbers indicate a transitional phase in which the company shifts from reliance on test strip sales to recurring software and sensor-linked revenue streams. As the global CGM market grows toward USD 18.00 billion in 2026, Roche’s ability to monetize data services and integration will be crucial for improving its market share.
Roche’s strategic strengths include strong brand recognition among diabetes patients, a large installed base of glucose monitoring devices and established relationships with clinics, pharmacies and payers worldwide. By focusing on interoperable digital health platforms that can ingest CGM, SMBG and other biomarker data, Roche differentiates itself as a data integration and decision-support specialist. This approach allows it to remain highly relevant in the CGM value chain even when it is not the primary sensor vendor.
-
Novo Nordisk A/S:
Novo Nordisk A/S, a global leader in insulin and GLP-1 therapies, influences the Continuous Glucose Monitoring market from the pharmacological side of diabetes care. While it does not manufacture CGM sensors, Novo Nordisk is an important strategic stakeholder because CGM data are increasingly used to optimize dosing of its injectable and oral therapies, inform clinical guidelines and support outcomes-based contracts with payers. The company leverages CGM-generated real-world evidence to demonstrate the value of its treatments in improving time-in-range and reducing hypoglycemia.
Novo Nordisk’s revenue directly attributable to CGM-linked digital programs, partnerships and data-driven outcome initiatives is estimated at USD 0.40 billion in 2025, equating to an approximate market share of 2.40% within the broader CGM-dependent services and solutions segment. These figures highlight the company’s role in monetizing CGM-enabled therapy optimization rather than in sensor hardware sales. As more payers incorporate CGM metrics into reimbursement decisions, Novo Nordisk’s investment in CGM analytics becomes strategically more valuable.
Novo Nordisk’s primary advantages in this context include its deep clinical expertise in diabetes pharmacotherapy, extensive global market access and the ability to fund large-scale CGM-based clinical trials. By partnering with CGM manufacturers and digital health companies, it integrates sensor data into patient-support apps, titration tools and remote monitoring platforms. This synergy differentiates Novo Nordisk as a therapy company that understands and leverages CGM insights, strengthening its position in outcomes-focused diabetes care models.
-
Menarini Diagnostics:
Menarini Diagnostics participates in the Continuous Glucose Monitoring market primarily within Europe, leveraging its diagnostic distribution networks and experience in point-of-care testing. While its presence in CGM is smaller than that of global leaders, Menarini acts as a regional accelerator of adoption, particularly in Southern Europe, where its brand is well known among laboratories, clinics and pharmacies. The company’s strategy often involves partnering with CGM technology providers to broaden local access.
In 2025, Menarini’s CGM-related revenue is projected at USD 0.16 billion, representing an estimated market share of 1.00%. These figures reflect a focused, regionally concentrated presence rather than a global footprint. However, within its core markets, Menarini can exert a disproportionate influence by aligning CGM promotion with its broader diagnostic product portfolio and existing payer contracts.
Menarini’s competitive strengths lie in its strong local market knowledge, extensive sales and service infrastructure and credibility with healthcare professionals in targeted European countries. By integrating CGM offerings into broader chronic disease diagnostic packages, it creates bundled value propositions that support health system efficiency. Compared with multinational CGM brands, Menarini differentiates through regional agility, localized support and the ability to tailor commercialization strategies to specific reimbursement and practice patterns.
-
AgaMatrix Inc.:
AgaMatrix Inc., known for its blood glucose monitoring technology, has extended its capabilities into the Continuous Glucose Monitoring space with a focus on sensor innovation and connected diabetes devices. Its role in the market is that of a nimble technology developer seeking to carve out niches in cost-sensitive segments and among patients transitioning from traditional fingerstick testing. The company emphasizes accuracy, connectivity and user-friendly mobile integration.
For 2025, AgaMatrix’s CGM-related revenue is estimated at USD 0.10 billion, with a corresponding market share of approximately 0.60%. These values indicate an early-stage presence relative to dominant incumbents, but they also suggest measurable traction in selected markets and channels. Growth potential will depend on the company’s ability to secure regulatory clearances, negotiate reimbursement and demonstrate compelling cost-to-benefit ratios compared with larger brands.
AgaMatrix’s competitive differentiation arises from its heritage in glucose measurement accuracy, compact device design and emphasis on smartphone-centric user experiences. By offering interoperable solutions that can integrate with third-party platforms, the company positions itself as a flexible partner within the CGM ecosystem. Compared with large diversified players, AgaMatrix can innovate quickly and target underserved or price-sensitive segments with tailored offerings.
-
GlySens Incorporated:
GlySens Incorporated is an innovation-driven company in the Continuous Glucose Monitoring sector, focusing on long-term implantable CGM platforms designed for multi-month sensor life. Its approach aims to reduce the frequency of sensor replacements, thereby improving patient adherence and quality of life. This technology model resembles that of other implantable CGM pioneers but seeks to optimize sensor longevity, signal stability and biocompatibility.
In 2025, GlySens’ revenue is projected at around USD 0.07 billion, corresponding to an estimated market share of 0.40%. These figures indicate a nascent but strategically significant position, particularly within the subset of patients and providers who favor long-duration implantable solutions over transcutaneous wearables. As clinical evidence accumulates and regulatory pathways mature, GlySens could benefit from the broader CGM market growth toward USD 30.60 billion by 2032.
GlySens’ key advantages center on its proprietary sensor designs, focus on long-term implantation and engineering expertise in signal processing over extended periods. By targeting patients who struggle with adherence to frequent sensor changes, GlySens addresses a specific unmet need in CGM. Compared with leaders in short-wear sensors, the company competes on durability, reduced maintenance and potential improvements in long-term adherence rather than on immediate large-scale volume.
-
POCTech Co. Ltd.:
POCTech Co. Ltd., based in China, is an important regional player in the Continuous Glucose Monitoring market, providing sensor systems tailored to the needs of emerging markets with growing diabetes prevalence. Its role is particularly notable in Asia, where it contributes to expanding access to CGM technology in both private and public healthcare settings. POCTech focuses on offering cost-effective CGM solutions that can be deployed at scale in health systems with constrained budgets.
By 2025, POCTech’s CGM revenue is estimated at USD 0.21 billion, representing an approximate market share of 1.30%. These numbers underscore a meaningful regional presence that complements, and occasionally competes with, global brands entering the Chinese and broader Asian CGM markets. The company’s growth trajectory is closely linked to national reimbursement policies, tender outcomes and the rapid increase in diabetes diagnosis rates across the region.
POCTech’s strategic strengths include competitive pricing, localization of products and interfaces for Chinese and other Asian languages, and an understanding of regional clinical practices. By aligning its CGM systems with local telemedicine platforms and hospital information systems, POCTech enhances physician adoption and integration into routine care. Compared with multinational players, the company differentiates through local regulatory agility, culturally adapted patient education and the ability to respond quickly to country-specific procurement requirements.
-
Nemaura Medical Inc.:
Nemaura Medical Inc. is an emerging innovator in the Continuous Glucose Monitoring field, focusing on non-invasive or minimally invasive CGM technologies that aim to reduce or eliminate the need for traditional sensor insertions. Its approach seeks to address patient hesitancy related to needle-based devices and to open CGM usage to broader populations, including pre-diabetes and wellness-oriented segments. This positions Nemaura at the intersection of medical-grade CGM and consumer-oriented metabolic monitoring.
In 2025, Nemaura’s CGM-related revenue is projected at USD 0.09 billion, with an estimated market share of 0.50%. These figures reflect an early-stage but strategically interesting footprint within a market that increasingly values patient comfort and preventive monitoring. If non-invasive technologies achieve robust clinical validation and regulatory endorsement, Nemaura could capture a growing portion of incremental demand beyond traditional insulin-dependent users.
Nemaura’s competitive differentiation derives from its focus on non-invasive sensing modalities, integration with smartphone applications and appeal to both clinical and wellness channels. By targeting patients who are reluctant to adopt conventional CGM, the company addresses a segment that remains largely untapped by incumbent sensor manufacturers. Compared with established players, Nemaura competes on comfort, convenience and potential applicability to broader metabolic health monitoring rather than on high-intensity insulin management alone.
Key Companies Covered
Dexcom Inc.
Abbott Laboratories
Medtronic plc
The Ypsomed Group
Senseonics Holdings Inc.
Ascensia Diabetes Care
Insulet Corporation
Tandem Diabetes Care Inc.
Roche Diabetes Care
Novo Nordisk A/S
Menarini Diagnostics
AgaMatrix Inc.
GlySens Incorporated
POCTech Co. Ltd.
Nemaura Medical Inc.
Market By Application
The Global Continuous Glucose Monitoring Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Type 1 diabetes management:
Type 1 diabetes management represents the anchor application for continuous glucose monitoring, as individuals with absolute insulin deficiency require intensive, round-the-clock glycemic surveillance. The core business objective in this segment is to minimize acute complications while maintaining tight glucose control to prevent long-term microvascular and macrovascular damage. Continuous monitoring enables high-frequency data capture, often exceeding 250 readings per day, which is not achievable with conventional fingerstick testing and provides a richer basis for insulin titration and behavioral adjustments.
Adoption is justified by clear operational outcomes such as increased time-in-range and fewer severe hypoglycemic events, which directly reduce emergency interventions and associated healthcare costs. Many real-world deployments report time-in-range improvements of more than 10.00 percentage points when patients transition from self-monitoring of blood glucose to continuous monitoring, leading to better day-to-day stability and fewer work or school disruptions. Growth in this application is primarily driven by expanding reimbursement coverage, earlier diagnosis of type 1 diabetes in younger populations, and integration with automated insulin delivery systems that further enhance clinical performance and user convenience.
-
Type 2 diabetes management:
Type 2 diabetes management is emerging as the largest incremental application opportunity for continuous glucose monitoring, given the high global prevalence of insulin-treated and non–insulin-treated type 2 patients. The business objective here is to optimize therapy intensity, support lifestyle modification and reduce hospitalization rates by identifying glycemic patterns that are invisible to episodic testing. Continuous monitoring allows clinicians and payers to quantify postprandial excursions and nocturnal hyperglycemia, which are common in type 2 diabetes and strongly associated with cardiovascular risk.
The unique operational outcome of continuous monitoring in this cohort is the ability to demonstrate rapid, data-driven improvements in glycemic metrics following medication adjustments or dietary changes, which can accelerate treatment cycles. Programs incorporating continuous monitoring often achieve measurable reductions in glycated hemoglobin within a few months, translating into lower complication risk and fewer costly acute events for a significant portion of participants. Growth in this application is catalyzed by value-based care models, employer-sponsored diabetes management programs and guideline updates that increasingly recognize continuous monitoring as a tool for complex or poorly controlled type 2 cases.
-
Gestational diabetes management:
Gestational diabetes management focuses on pregnant individuals who develop glucose intolerance, where the primary objective is to maintain tight glycemic control to protect both maternal and fetal health. Continuous glucose monitoring is particularly significant in this application because short-term glycemic excursions can influence birth weight, cesarean delivery rates and neonatal intensive care admissions. The technology supports more precise adjustments of diet, physical activity and insulin dosing in a time-sensitive clinical window that typically spans only a few months.
The operational advantage of continuous monitoring over traditional self-monitoring in gestational diabetes lies in its ability to uncover nocturnal and post-meal spikes that may be missed with limited fingerstick checks. Clinics using continuous monitoring can rapidly evaluate the impact of dietary counseling and therapy changes over several days, reducing the trial-and-error period and enhancing adherence. Growth in this segment is driven by rising global rates of obesity and advanced maternal age, along with heightened obstetric focus on reducing macrosomia and neonatal complications that generate substantial hospital costs.
-
Hospital and critical care glucose monitoring:
Hospital and critical care glucose monitoring uses continuous systems to manage glycemia in intensive care units, perioperative settings and high-acuity wards. The main business objective is to reduce complications associated with both hyperglycemia and hypoglycemia in hospitalized patients, which can extend length of stay and increase mortality. Continuous data streams help clinicians titrate intravenous or subcutaneous insulin protocols more precisely than intermittent laboratory or bedside measurements.
Adoption is justified by operational outcomes such as reduced nursing workload, fewer manual glucose checks and more stable glycemic profiles, which can lower rates of infection and organ dysfunction in critical care environments. Deployments targeting high-risk cohorts often log significant reductions in extreme glucose excursions, contributing to shorter intensive care unit stays and improved bed turnover efficiency. Growth in this application is fueled by hospital cost-containment pressures, initiatives to standardize inpatient glycemic management and technological advances that improve sensor accuracy and reliability in hemodynamically unstable patients.
-
Preventive and wellness glucose monitoring:
Preventive and wellness glucose monitoring addresses health-conscious consumers, prediabetic individuals and athletes who use continuous data to optimize lifestyle and metabolic health. The core objective is to identify personalized responses to diet, exercise and sleep before the onset of overt diabetes or cardiovascular disease, thereby reducing long-term healthcare expenditures. These users value real-time feedback on how specific foods or activities affect glucose curves, turning metabolic control into a daily performance metric.
The unique operational outcome of continuous monitoring in the wellness segment is behavioral optimization, as users can see immediate, quantified impacts of their decisions, which increases adherence to nutrition plans and activity regimens. Digital health programs that bundle continuous monitoring with coaching frequently report substantial improvements in weight, insulin sensitivity proxies and self-reported energy levels across a significant portion of their user base. Growth in this application is driven by direct-to-consumer digital platforms, employer wellness initiatives and expanding awareness of metabolic health as a strategic component of long-term productivity and quality of life.
-
Clinical research and drug development glucose monitoring:
Clinical research and drug development glucose monitoring leverages continuous data to evaluate the efficacy and safety of novel therapeutics, devices and digital interventions. The business objective is to generate high-resolution, statistically robust endpoints that can shorten trial timelines and improve the probability of regulatory approval. Continuous monitoring enables capture of thousands of data points per subject over a study period, significantly increasing analytical power compared with sparse sampling approaches.
The operational advantage in research settings is the capacity to quantify metrics such as time-in-range, glycemic variability and nocturnal hypoglycemia with precision, which supports nuanced differentiation between competing drug candidates or delivery technologies. By reducing data gaps and measurement noise, continuous monitoring can lower required sample sizes or follow-up durations in some study designs, improving overall development productivity and return on research investment. Growth in this application is propelled by the expansion of cardiometabolic pipelines, regulatory openness to digital biomarkers and the rising use of decentralized and hybrid clinical trial models that depend on reliable remote data capture.
Key Applications Covered
Type 1 diabetes management
Type 2 diabetes management
Gestational diabetes management
Hospital and critical care glucose monitoring
Preventive and wellness glucose monitoring
Clinical research and drug development glucose monitoring
Mergers and Acquisitions
The continuous glucose monitoring market has experienced an active cycle of mergers and acquisitions over the last 24 months, driven by rapid sensor innovation and reimbursement expansion. Deal flow has concentrated around established CGM leaders acquiring algorithm, connectivity, and digital coaching assets to build closed-loop ecosystems. At the same time, diversified medtech and consumer-health platforms are buying their way into real-time glucose analytics as they seek exposure to a market expected to reach USD 16.50 Billion in 2025, with a CAGR of 9.10 percent supporting premium valuations.
Major M&A Transactions
Dexcom – TypeZero Technologies
Integration of advanced insulin dosing algorithms to accelerate fully automated closed-loop systems.
Abbott – Bigfoot Biomedical
Expansion from sensors into end-to-end insulin management using AI-enabled dosing decision support.
Medtronic – EOFlow
Acquisition of patch pump technology to strengthen hybrid closed-loop CGM and insulin delivery portfolio.
Roche – Senseonics Partnership Buyout
Securing long-term implantable CGM capabilities for differentiated wear-time and accuracy positioning.
Sanofi – Biocorp
Bolstering connected drug-delivery devices to link CGM data with insulin pen adherence analytics.
Novo Nordisk – Eversense Distribution Rights
Access to long-wear implantable CGM to complement GLP-1 and insulin therapy bundles.
Dexcom – Hygieia Digital Insulin Services
Enhancing cloud-based insulin titration services tightly integrated with CGM data streams.
Abbott – Tidepool Data Platform Assets
Consolidation of multi-device interoperability to anchor open-data CGM ecosystems.
Recent consolidation is concentrating market power in a handful of global CGM platforms, which now control a significant portion of installed sensor bases and cloud data. Acquirers prioritize vertical integration of sensors, insulin delivery, and decision-support software, compressing competitive space for standalone device manufacturers. This concentration raises barriers to entry, particularly in payer negotiations where scale and outcome data increasingly determine formulary access and pricing leverage.
Valuation multiples in CGM-related transactions have remained elevated relative to broader medtech, supported by ReportMines’s forecast of the market reaching USD 30.60 Billion by 2032. Deals involving differentiated software algorithms, long-wear implants, or patch pumps have commanded revenue multiples that price in future bundled-therapy revenues rather than stand-alone device sales. Strategic buyers accept these premiums because integrated CGM ecosystems provide cross-selling opportunities into insulin, GLP-1 therapies, and virtual diabetes clinics.
From a strategic positioning standpoint, incumbents use acquisitions to close feature gaps ahead of next-generation launches, such as calibration-free sensors and factory-integrated closed-loop systems. At the same time, pharmaceutical companies are building CGM-enabled therapy bundles, positioning glucose data as a companion diagnostic for metabolic drugs. This blurs traditional boundaries between devices, digital health, and therapeutics, and it rewards platforms capable of demonstrating reductions in hypoglycemia events and hospitalizations in real-world datasets.
Regionally, North America continues to dominate deal values, with acquirers targeting U.S.-based software and sensor innovators to secure FDA-cleared platforms and access to large commercial insurance populations. Europe contributes a significant portion of algorithm and cloud interoperability targets, often acquired for GDPR-compliant architectures that can be scaled globally. In Asia-Pacific, strategic investors focus on local manufacturing, low-cost sensors, and smartphone-centric CGM apps tailored to large type 2 diabetes populations.
Technology themes shaping the mergers and acquisitions outlook for Continuous Glucose Monitoring Market include factory-calibrated sensors, multi-analyte biosensing, and AI engines that translate glucose trends into automated therapy adjustments. Buyers also prioritize interoperability with wearables, smartphones, and insulin pumps, aiming to offer seamless user experiences that lock in patients over multiple upgrade cycles. These technology-driven deals will influence future competitive entry points, making partnerships essential for smaller innovators.
Competitive LandscapeRecent Strategic Developments
In January 2024, Dexcom announced a strategic expansion and integration initiative with multiple insulin pump and digital therapeutic partners, focused on broadening interoperability for its G7 continuous glucose monitoring system. This development intensified competition in closed-loop diabetes management by strengthening Dexcom’s ecosystem positioning and raising the integration benchmark for rival CGM vendors. It also accelerated payer interest in reimbursing fully connected diabetes care pathways rather than stand-alone sensors.
In March 2024, Abbott pursued a strategic investment and partnership program to scale its FreeStyle Libre portfolio into primary care and employer-based wellness channels. By shifting distribution beyond endocrinology centers, this move expanded the addressable patient population, increased pressure on smaller CGM manufacturers in retail and pharmacy channels, and reinforced Abbott’s pricing leverage in large-volume contracts with health plans and integrated delivery networks.
In June 2023, Medtronic completed an expansion of its diabetes division through targeted acquisitions of sensor technology and algorithm assets. This sharpened Medtronic’s capability in real-time analytics, improved its hybrid closed-loop offering, and forced competitors to accelerate innovation cycles to defend premium segments of the CGM market.
SWOT Analysis
-
Strengths:
The global Continuous Glucose Monitoring market benefits from strong clinical validation, rapidly improving sensor accuracy, and robust reimbursement momentum in major healthcare systems. CGM systems deliver continuous, real-time glycemic data, enabling tight glycemic control, reduced incidence of severe hypoglycemia, and fewer diabetes-related hospitalizations, which makes them attractive to payers and integrated delivery networks. The market is also reinforced by powerful brands and established installed bases from leading players, which support recurring revenue through sensor cartridges and subscription-based digital platforms. Interoperability with insulin pumps, smart pens, and diabetes management apps is further embedding CGM solutions at the center of automated insulin delivery ecosystems and remote patient monitoring workflows.
-
Weaknesses:
Despite its advantages, the Continuous Glucose Monitoring market faces weaknesses related to high device and consumable costs, which limit penetration among underinsured patients and in cost-sensitive emerging economies. Many CGM systems still require periodic fingerstick calibration in certain use cases, and sensor wear time, skin irritation, and adhesive failures can reduce patient adherence. Data overload and user interface complexity may overwhelm newly diagnosed patients or older adults, leading to underutilization of advanced analytics. In addition, reliance on proprietary communication protocols and closed data ecosystems can create integration friction for health systems and app developers, while ongoing cybersecurity and data privacy concerns add compliance burdens for manufacturers.
-
Opportunities:
The Continuous Glucose Monitoring market has substantial opportunities to expand beyond intensive insulin users into broader Type 2 diabetes and prediabetes populations through simplified, lower-cost sensors and intermittent scanning models. Integration with telehealth platforms, population health analytics, and employer-sponsored metabolic wellness programs can unlock new recurring revenue streams and support value-based care contracts. Advancements in minimally invasive or non-invasive sensor technologies, such as optical or microneedle-based systems, create opportunities to improve patient comfort and extend wear duration. Emerging markets in Asia-Pacific, Latin America, and the Middle East represent high-growth regions as healthcare infrastructure improves and payers recognize the long-term cost savings associated with reduced diabetes complications and hospital utilization.
-
Threats:
The Continuous Glucose Monitoring market faces threats from intensifying price competition, reference pricing, and reimbursement pressure, which could compress margins on sensors and transmitters. New entrants developing non-invasive glucose monitoring through consumer wearables, such as smartwatches or multi-sensor fitness devices, may displace traditional transcutaneous sensors in selected segments if accuracy reaches regulatory standards. Regulatory scrutiny around data security, algorithm transparency, and real-world performance may delay product launches or require costly post-market surveillance. Supply chain disruptions affecting semiconductor components, biosensors, and medical-grade adhesives can constrain production, while consolidation among payers and pharmacy benefit managers increases bargaining power and may favor a limited number of preferred CGM vendors.
Future Outlook and Predictions
The global Continuous Glucose Monitoring market is expected to expand steadily over the next decade, with ReportMines projecting growth from USD 16.50 Billion in 2025 to USD 30.60 Billion by 2032, implying a CAGR of 9.10 percent. Over the next 5–10 years, this trajectory indicates that CGM will shift from a specialist tool for intensive insulin users to a mainstream standard of care for a substantial portion of people with Type 2 diabetes. Payers are likely to support this diffusion as evidence continues to link CGM-driven time-in-range improvements to lower hospitalization rates, reduced complications, and better productivity outcomes.
Technological evolution will center on sensor miniaturization, longer wear duration, and factory-calibrated devices that eliminate routine fingersticks. Leading manufacturers are already prioritizing single-use, disposable transmitters and integrated sensor–transmitter patches, and this trend is expected to accelerate. In parallel, algorithmic innovation will refine predictive alerts and insulin dosing guidance, transforming CGM systems into proactive metabolic decision-support tools rather than passive monitoring devices. These advances will raise performance expectations and intensify product upgrade cycles.
Closed-loop and interoperable ecosystems will likely become the dominant competitive battleground. Integration of CGM sensors with insulin pumps, smart pens, and connected inhaled insulin will expand fully or semi-automated insulin delivery to a larger share of Type 1 and insulin-intensive Type 2 patients. Application programming interfaces that allow CGM data to flow into digital therapeutics, nutrition platforms, and broader chronic-care apps will also differentiate vendors, as health systems increasingly favor interoperable, vendor-agnostic architectures when negotiating long-term contracts.
Regulatory and reimbursement frameworks are expected to become more supportive but also more demanding. Many regulators are moving toward streamlined pathways for iterative CGM upgrades, particularly when improvements are software-driven. At the same time, authorities are increasing scrutiny of cybersecurity, clinical validation in diverse populations, and real-world performance metrics such as accuracy in hypo- and hyperglycemic ranges. Reimbursement policies are likely to evolve toward value-based models that reward reductions in total cost of care, encouraging CGM suppliers to bundle sensors with coaching, analytics, and telemonitoring services.
Economically, price pressure will intensify as large payers, national health systems, and pharmacy benefit managers consolidate purchasing power. Over the next decade, this dynamic will likely drive tiered product portfolios, with premium, feature-rich CGM systems targeting intensive users and lower-cost, intermittent or simplified sensors directed at broad primary-care and employer-wellness segments. Competitors that can localize manufacturing, optimize supply chains, and tailor offerings for emerging markets are positioned to capture a significant portion of incremental volume growth, particularly in Asia-Pacific and Latin America.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Continuous Glucose Monitoring Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Continuous Glucose Monitoring by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Continuous Glucose Monitoring by Country/Region, 2017,2025 & 2032
- 2.2 Continuous Glucose Monitoring Segment by Type
- Sensor-based continuous glucose monitoring systems
- Integrated insulin pump and continuous glucose monitoring systems
- Standalone continuous glucose monitoring transmitters and receivers
- Continuous glucose monitoring data management and analytics software
- Professional and clinic-based continuous glucose monitoring systems
- Continuous glucose monitoring accessories and consumables
- 2.3 Continuous Glucose Monitoring Sales by Type
- 2.3.1 Global Continuous Glucose Monitoring Sales Market Share by Type (2017-2025)
- 2.3.2 Global Continuous Glucose Monitoring Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Continuous Glucose Monitoring Sale Price by Type (2017-2025)
- 2.4 Continuous Glucose Monitoring Segment by Application
- Type 1 diabetes management
- Type 2 diabetes management
- Gestational diabetes management
- Hospital and critical care glucose monitoring
- Preventive and wellness glucose monitoring
- Clinical research and drug development glucose monitoring
- 2.5 Continuous Glucose Monitoring Sales by Application
- 2.5.1 Global Continuous Glucose Monitoring Sale Market Share by Application (2020-2025)
- 2.5.2 Global Continuous Glucose Monitoring Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Continuous Glucose Monitoring Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report